Loading institutional data...
Loading institutional data...
Institutional accumulation: ownership increased +2.50% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.18B 100.0% | $2.03B 100.0% | $1.39B 100.0% | $1.14B 100.0% | $773.9M 100.0% | $687.2M 100.0% | $560.6M 100.0% | $519.9M 100.0% | $356.4M 100.0% | $57.4M 100.0% |
| Cost of Revenue | — | — | — | — | $596.1M 77.0% | $539.2M 78.5% | $467.8M 83.4% | $361.1M 69.5% | $273.5M 76.7% | — |
| Cost of Services | — | — | — | — | — | — | — | — | $274.7M 77.1% | $48.7M 84.9% |
| Selling, General & Admin | $217.3M 6.8% | $154.1M 7.6% | $112.6M 8.1% | $77.7M 6.8% | $62.1M 8.0% | $49.1M 7.1% | $41.5M 7.4% | $43.4M 8.3% | $26.2M 7.4% | $18.6M 32.4% |
| Total Operating Expenses | $3.10B 97.5% | $1.95B 95.6% | $1.30B 93.9% | $1.04B 90.9% | $675.7M 87.3% | $606.7M 88.3% | $528.2M 94.2% | $431.5M 83.0% | $321.2M 90.1% | $68.0M 118.3% |
| Operating Income | $78.5M 2.5% | $89.3M 4.4% | $84.6M 6.1% | $104.3M 9.1% | $98.2M 12.7% | $80.5M 11.7% | $32.4M 5.8% | $88.4M 17.0% | $35.1M 9.9% | -$10.5M -18.3% |
| Interest Expense | $49.9M 1.6% | $33.1M 1.6% | $16.1M 1.2% | $7.9M 0.7% | $5.4M 0.7% | $9.5M 1.4% | $4.7M 0.8% | $561K 0.1% | $80K 0.0% | $83K 0.1% |
| Interest & Investment Income | $12.2M 0.4% | $14.5M 0.7% | $14.2M 1.0% | $2.0M 0.2% | $1.6M 0.2% | $2.8M 0.4% | $2.0M 0.4% | $1.3M 0.2% | $1.0M 0.3% | — |
| Other Income (Expense), net | -$38.9M -1.2% | -$8.5M -0.4% | $5.2M 0.4% | -$17.6M -1.5% | -$20.4M -2.6% | $97.9M 14.3% | -$6.6M -1.2% | -$5.8M -1.1% | $14.6M 4.1% | $1.8M 3.1% |
| Pretax Income | $39.6M 1.2% | $80.8M 4.0% | $89.8M 6.5% | $86.6M 7.6% | $77.7M 10.0% | $178.4M 26.0% | $25.8M 4.6% | $82.6M 15.9% | $49.7M 13.9% | -$8.7M -15.2% |
| Income Tax Expense | $15.5M 0.5% | $30.9M 1.5% | $32.0M 2.3% | $40.9M 3.6% | $31.7M 4.1% | $56.3M 8.2% | $8.2M 1.5% | $22.4M 4.3% | $3.9M 1.1% | -$47K -0.1% |
| Net Income | $24.0M 0.8% | $50.0M 2.5% | $58.0M 4.2% | $46.0M 4.0% | $46.0M 5.9% | $37.7M 5.5% | $14.1M 2.5% | $10.8M 2.1% | $25.8M 7.2% | -$9.0M -15.6% |
| Per Share | ||||||||||
| EPS (Basic) | $0.46 | $0.91 | $1.30 | $1.00 | $1.57 | $1.03 | $0.41 | $0.33 | $1.01 | — |
| EPS (Diluted) | $0.46 | $0.90 | $1.29 | $0.99 | $1.52 | $1.01 | $0.39 | $0.29 | $0.90 | — |
| Weighted Avg Shares (Basic) | 49.1M | 47.6M | 46.6M | 45.0M | 43.8M | 36.5M | 34.7M | 32.9M | 25.5M | — |
| Weighted Avg Shares (Diluted) | 49.4M | 48.0M | 46.9M | 45.6M | 45.4M | 37.4M | 36.4M | 37.9M | 28.7M | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $34.30 today, the market must believe free cash flow compounds 15.9%/yr for a decade (off $63M normalized FCF).
The market's 15.9% is more optimistic than its 8-yr track record.
2-stage DCF · 0.05B shares · net debt $609M
mean 37.7% · volatility σ 107% · implied rate exceeded in 2/8 yrs
Central path = implied 15.9%/yr growth; shaded band = ±1σ (107%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
3/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 8% of free cash flow, leaving room to grow it and fund buybacks. Last year: $8M dividends + $26M buybacks = $33M returned on $104M FCF.
1 consecutive years of dividend increases · -8%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 1%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $429M covers all $282M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2023-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~4.8% on $1.0B of debt.
Cash of $429M fully covers short-term debt of $48M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ASTH | $1.7B | 74.6× | 18.4× | 0.5× | 56.4% | — | 0.7% | 2.9% | 1.2% | 8.4× | 162 |
Peers = companies sharing ASTH's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Where each multiple sits in its own 13-yr range · 54th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 13-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 69.5 | 83.4 | 78.5 | 77.0 | — | — | — | — |
| SG&A | 8.3 | 7.4 | 7.1 | 8.0 | 6.8 | 8.1 | 7.6 | 6.8 |
| Operating Income | 17.0 | 5.8 | 11.7 | 12.7 | 9.1 | 6.1 | 4.4 | 2.5 |
| Income Tax | 4.3 | 1.5 | 8.2 | 4.1 | 3.6 | 2.3 | 1.5 | 0.5 |
| Net Income | 2.1 | 2.5 | 5.5 | 5.9 | 4.0 | 4.2 | 2.5 | 0.8 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ASTH: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.